Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Tandem Diabetes Care ( (TNDM) ) is now available.
On December 26, 2025, Tandem Diabetes Care’s board of directors approved Amended and Restated Bylaws as part of a periodic governance review, immediately replacing the prior bylaws. The revisions significantly update advance notice requirements for shareholder director nominations and other proposals, tightening disclosure obligations, limiting the number of nominees to the seats up for election, restricting substitute nominees, and enabling the company to disregard nominations if shareholders fail to comply with federal proxy rules or do not appear to present their nominees. Additional changes formalize the board’s authority to cancel, reschedule or postpone shareholder meetings, reserve the white proxy card exclusively for the board, modernize indemnification and notice provisions in line with Delaware corporate law, simplify and clarify voting standards for director elections, and remove the requirement to provide a physical shareholder list at meetings. Collectively, these amendments streamline corporate governance, reinforce the board’s control over the shareholder meeting and proxy process, and may shape how activist investors and other shareholders engage with the company in future contested or routine elections.
The most recent analyst rating on (TNDM) stock is a Hold with a $24.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.
Spark’s Take on TNDM Stock
According to Spark, TipRanks’ AI Analyst, TNDM is a Neutral.
Tandem Diabetes Care’s overall stock score reflects a mix of financial challenges and positive strategic developments. The financial performance is a significant concern due to declining revenue and high leverage. However, strong technical indicators and positive earnings call sentiment provide a more optimistic outlook. The recent board appointment further supports the company’s strategic direction.
To see Spark’s full report on TNDM stock, click here.
More about Tandem Diabetes Care
Tandem Diabetes Care, Inc. operates in the medical device industry, focusing on diabetes management technologies. The company is best known for its insulin delivery systems, including insulin pumps and related software, serving patients with insulin-dependent diabetes and the healthcare providers who treat them.
Average Trading Volume: 2,059,632
Technical Sentiment Signal: Sell
Current Market Cap: $1.51B
Learn more about TNDM stock on TipRanks’ Stock Analysis page.